Printer Friendly

Casma Therapeutics Establishes Scientific Advisory Board with Appointments of Autophagy and Neuroscience Researchers.

M2 PHARMA-March 28, 2019-Casma Therapeutics Establishes Scientific Advisory Board with Appointments of Autophagy and Neuroscience Researchers

(C)2019 M2 COMMUNICATIONS

- US-based biotechnology company Casma Therapeutics, Inc has appointed Sascha Martens, Ph.D., and Pietro De Camilli, M.D., as the first members of Casma's scientific advisory board, the company said.

Martens, an expert in autophagy research, is currently professor and head of the department of biochemistry and cell biology at the Max F. Perutz Laboratories at the University of Vienna, Austria.

De Camilli is based at the Yale School of Medicine, where he is the John Klingenstein Professor of Neuroscience and professor of cell biology, chair of the department of neuroscience and director of the Kavli Institute for Neuroscience.

Professor De Camilli is also an investigator at the Howard Hughes Medical Institute.

Sascha Martens has worked at the MFPL, University of Vienna for nearly 10 years in roles of increasing seniority.

As a principal investigator, Martens leads research on the foundations of autophagy, exploring how the numerous factors required for autophagy work together to form the autophagosomes that engulf and dispose of harmful cellular material.

He is the author of dozens of papers on the factors and processes involved in autophagy and has received several prestigious research grants, including the Human Frontier Science Program grant and the European Research Council Consolidator grant.

He has a diploma degree in biology and a Ph.D. in genetics from the Institute for Genetics of the University of Cologne, Germany, where he was awarded the Klaus Liebrecht Prize for one of the two best master or Ph.D. studies within the university's math and science departments.

He conducted postdoctoral research at the Institute for Genetics of the University of Cologne, Germany and at the Medical Research Council Laboratory of Molecular Biology in Cambridge, UK.

Pietro De Camilli joined the Yale School of Medicine in 1988 and subsequently became a Howard Hughes Medical Institute investigator in 1992. He served for three years as chair of the department of cell biology and was the founding director of the Yale Program in Cellular Neuroscience, Neurodegeneration and Repair.

As a principal investigator, he leads research on the cell biology of neuronal synapses, with the long-term goal of advancing understanding of nervous system function in human disease.

De Camilli was awarded the Julius Axelrod Prize from the Society for Neuroscience in 2015. He is an elected member of the National Academy of Sciences, the National Academy of Medicine, the American Academy of Arts and Sciences and the European Molecular Biology Organization, among other organizations.

In 2017 he served as president of the American Society for Cell Biology. He earned his M.D. from the University of Milan, Italy and has a postgraduate degree in medical endocrinology from the University of Pavia in Italy.

Casma Therapeutics is harnessing the natural cellular process of autophagy to open new target areas for drug discovery and development.

The company uses several approaches to intervene at strategic points throughout the autophagy-lysosome system to improve the cellular process of clearing out unwanted proteins, organelles and invading pathogens.

By boosting autophagy, Casma expects to be able to arrest or reverse the progression of lysosomal storage disorders, muscle disorders, inflammatory disorders and neurodegeneration, among other indications.

Casma was launched in 2018 by Third Rock Ventures and is based in Cambridge, Mass.

((Comments on this story may be sent to info@m2.com))
COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Mar 28, 2019
Words:565
Previous Article:Initial Phase 2 Data from an IMV Clinical Study Continues to Demonstrate DPX-Survivac's Prior Trend as a Potential Monotherapy Treatment for Advanced...
Next Article:Ichor Medical Systems Forges Collaboration and Research License Agreement with AstraZeneca to Develop DNA-based Monoclonal Antibody Platform.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters